NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Sep. 30, 2015

Schedule of assets and liabilities measured and recognized at fair value

The following table presents assets and liabilities that are measured and recognized at fair value as of September 30, 2015 and 2014, on a recurring basis:

Assets and liabilities measured at fair value on a recurring basis at September 30, 2015	Level 1	Level 2	Level 3		Total Carrying Value
Contingent stock consideration	$	$	$	2,239,603	$	2,239,603
	$	$	$	2,239,603	$	2,239,603

Assets and liabilities measured at fair value on a recurring basis at September 30, 2014	Level 1	Level 2	Level 3		Total Carrying Value
Contingent stock consideration	$	$		4,877,359	$	4,877,359
	$	$		4,877,359	$	4,877,359

Schedule of fair value of financial instruments by caption on balance sheet

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:

Level 3 Reconciliation:	Stock Warrant Derivative			Contingent Stock Consideration
Level 3 assets and liabilities at September 30, 2012	$	(768,696	)	$
Purchases, sales, issuances and settlements (net)		1,886,338
Mark to market adjustments, net of gain on derivative liability of $55,481		(1,117,642	)
Level 3 assets and liabilities at September 30, 2013
Purchases, sales, issuances and settlements (net)					4,877,359
Mark to market adjustments
Level 3 assets and liabilities at September 30, 2014					4,877,359
Purchases, sales, issuances and settlements (net)
Mark to market adjustments					(2,637,756	)
Total Level 3 assets and liabilities at September 30, 2015	$			$	2,239,603